open access

Vol 51, No 3 (2020)
ORIGINAL RESEARCH ARTICLE
Submitted: 2020-03-08
Published online: 2020-09-01
Get Citation

Acute non-hematological toxicity of intensive chemotherapy of acute lymphoblastic leukemia in children

Ewa Demidowicz1, Natalia Bartoszewicz1, Krzysztof Czyżewski1, Joanna Cisek1, Anna Dąbrowska1, Robert Dębski1, Magdalena Dziedzic1, Marlena Ewertowska1, Elżbieta Grześk1, Agnieszka Jatczak-Gaca1, Andrzej Kołtan1, Sylwia Kołtan1, Anna Krenska1, Monika Łęcka1, Piotr Księżniakiewicz1, Agata Marjańska1, Monika Pogorzała1, Monika Richert-Przygońska1, Barbara Tejza1, Anna Urbańczyk1, Hanna Żołnowska1, Mariusz Wysocki1, Jan Styczyński1
DOI: 10.2478/ahp-2020-0029
·
Acta Haematol Pol 2020;51(3):164-171.
Affiliations
  1. Department of Pediatric Hematology and Oncology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Jurasz University Hospital 1, Bydgoszcz, Poland

open access

Vol 51, No 3 (2020)
ORIGINAL RESEARCH ARTICLE
Submitted: 2020-03-08
Published online: 2020-09-01

Abstract

Introduction

Leukemia belong to 31% of all childhood malignancies. Acute lymphoblastic leukemia (ALL) is the most frequent type of pediatric leukemia accounting for 80–85% of all cases. Progress in diagnostics and therapy of leukemia is dependent on international cooperation. The objective of the study was the analysis of non-hematological toxicity during intensive chemotherapy according to two consecutive intercontinental protocols.

Patients and methods

A total number of 210 children diagnosed for ALL who were treated in single center between 2002 and 2018 were divided in two groups defined by therapeutic protocol: ALL IC-BFM 2002 (group 1) and ALL IC-BFM 2009 (group 2). Data were entered prospectively from 2002 into international ALL IC-BFM 2002 and ALL IC-BFM 2009 registry. Non-hematological toxicity was analyzed according to the criteria followed in protocols, compatible with CTCAE criteria.

Results

The most frequent toxicities included hepatic toxicity with transaminitis and hyperbilirubinemia, infections, oral mucositis and gut toxicity with vomiting, and/or diarrhea. Non-hematological toxicity episodes calculated as a ratio per patient were comparably often observed in both the groups; however, the distribution was different. There were more grade III and less grade II toxicities. This was mainly related to significant increase in the rates of infections and transaminitis. However, there was a significant decrease in vomiting and central and peripheral neurotoxicity.

Conclusions

Intensive treatment of ALL is burdened with frequent severe toxic and infectious complications. Further progress in therapy of pediatric ALL is dependent on sophisticated supportive therapy and very well experienced and knowledgeable therapeutic team.

Abstract

Introduction

Leukemia belong to 31% of all childhood malignancies. Acute lymphoblastic leukemia (ALL) is the most frequent type of pediatric leukemia accounting for 80–85% of all cases. Progress in diagnostics and therapy of leukemia is dependent on international cooperation. The objective of the study was the analysis of non-hematological toxicity during intensive chemotherapy according to two consecutive intercontinental protocols.

Patients and methods

A total number of 210 children diagnosed for ALL who were treated in single center between 2002 and 2018 were divided in two groups defined by therapeutic protocol: ALL IC-BFM 2002 (group 1) and ALL IC-BFM 2009 (group 2). Data were entered prospectively from 2002 into international ALL IC-BFM 2002 and ALL IC-BFM 2009 registry. Non-hematological toxicity was analyzed according to the criteria followed in protocols, compatible with CTCAE criteria.

Results

The most frequent toxicities included hepatic toxicity with transaminitis and hyperbilirubinemia, infections, oral mucositis and gut toxicity with vomiting, and/or diarrhea. Non-hematological toxicity episodes calculated as a ratio per patient were comparably often observed in both the groups; however, the distribution was different. There were more grade III and less grade II toxicities. This was mainly related to significant increase in the rates of infections and transaminitis. However, there was a significant decrease in vomiting and central and peripheral neurotoxicity.

Conclusions

Intensive treatment of ALL is burdened with frequent severe toxic and infectious complications. Further progress in therapy of pediatric ALL is dependent on sophisticated supportive therapy and very well experienced and knowledgeable therapeutic team.

Get Citation

Keywords

acute lymphoblastic leukemia; chemotherapy; toxicity; children

About this article
Title

Acute non-hematological toxicity of intensive chemotherapy of acute lymphoblastic leukemia in children

Journal

Acta Haematologica Polonica

Issue

Vol 51, No 3 (2020)

Pages

164-171

Published online

2020-09-01

Page views

247

Article views/downloads

377

DOI

10.2478/ahp-2020-0029

Bibliographic record

Acta Haematol Pol 2020;51(3):164-171.

Keywords

acute lymphoblastic leukemia
chemotherapy
toxicity
children

Authors

Ewa Demidowicz
Natalia Bartoszewicz
Krzysztof Czyżewski
Joanna Cisek
Anna Dąbrowska
Robert Dębski
Magdalena Dziedzic
Marlena Ewertowska
Elżbieta Grześk
Agnieszka Jatczak-Gaca
Andrzej Kołtan
Sylwia Kołtan
Anna Krenska
Monika Łęcka
Piotr Księżniakiewicz
Agata Marjańska
Monika Pogorzała
Monika Richert-Przygońska
Barbara Tejza
Anna Urbańczyk
Hanna Żołnowska
Mariusz Wysocki
Jan Styczyński

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl